Grade 3 or higher adverse events included ascites ( 34 [ 8 % ] in the placebo group vs 52 [ 11 % ] in the trebananib group ) , neutropenia ( 40 [ 9 % ] vs 26 [ 6 % ] ) , and abdominal pain ( 21 [ 5 % ] vs 22 [ 5 % ] ) .